Patents by Inventor Lisa Hasvold

Lisa Hasvold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230158039
    Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: June 30, 2022
    Publication date: May 25, 2023
    Inventors: Le Wang, John K. Pratt, Keith F. McDaniel, Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James H. Holms, Warren M. Kati, Dachun Liu, Robert A. Mantei, William J. McClellan, George S. Sheppard, Carol K. Wada
  • Publication number: 20210236508
    Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: August 18, 2020
    Publication date: August 5, 2021
    Inventors: Le Wang, John K. Pratt, Keith F. McDaniel, Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James H. Holms, Warren M. Kati, Dachun Liu, Robert A. Mantei, William J. McClellan, George S. Sheppard, Carol K. Wada
  • Publication number: 20210130346
    Abstract: Compounds of formula (I), wherein R1, R2, R3, R5, R6, R7, A1, A2, A3, A4, X1, and X2 have any of the values defined in the specification and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS are provided. Pharmaceutical compositions comprising of compounds of formula (I) are also provided.
    Type: Application
    Filed: April 14, 2017
    Publication date: May 6, 2021
    Applicant: AbbVie Inc.
    Inventors: David Hardee, Jason Brewer, Lisa Hasvold, Dachun Liu, Keith McDaniel, Michael Schrimpf, George Sheppard
  • Publication number: 20210047304
    Abstract: The present invention provides for compounds of formula (I) wherein R1, Y, L1, G1, X1, X2, L2, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: May 26, 2020
    Publication date: February 18, 2021
    Inventors: Marlon Cowart, Steven Fidanze, Lisa Hasvold, Dachun Liu, Keith McDaniel, John Pratt, George Sheppard, Le Wang
  • Publication number: 20190382383
    Abstract: Provided herein are compounds of formula (I) wherein R1, Y, L1, G1, X1, X2, L2, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: October 14, 2016
    Publication date: December 19, 2019
    Inventors: Marlon Cowart, Steven Fidanze, Lisa Hasvold, Dachun Liu, Keith McDaniel, John Pratt, George Sheppard, Le Wang
  • Publication number: 20190084981
    Abstract: The present invention provides for compounds of formula (I) wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: November 16, 2018
    Publication date: March 21, 2019
    Inventors: Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James Holms, Dachun Liu, William McClellan, Keith McDaniel, Jasmina Marjanovic, George Sheppard, Le Wang
  • Patent number: 10131657
    Abstract: The present invention provides for compounds of formula (I). wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: November 20, 2018
    Assignee: AbbVie Inc.
    Inventors: Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James Holms, Dachun Liu, William McClellan, Keith McDaniel, Jasmina Marjanovic, George Sheppard, Le Wang
  • Publication number: 20180296566
    Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: June 19, 2018
    Publication date: October 18, 2018
    Inventors: Le Wang, John K. Pratt, Keith F. McDaniel, Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James H. Holms, Warren M. Kati, Dachun Liu, Robert A. Mantei, William J. McClellan, George S. Sheppard, Carol K. Wada
  • Publication number: 20180251426
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: October 13, 2017
    Publication date: September 6, 2018
    Inventors: Milan Bruncko, Yujia Dai, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura Hexamer, Aaron R. Kunzer, Robert A. Mantei, Chang H. Park, Cheol-Min Park, Andrew M. Petros, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, William J. McClellan
  • Patent number: 9957263
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compositions comprised of one or more compounds of formula (I) are also provided.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: May 1, 2018
    Assignee: AbbVie Inc.
    Inventors: Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James Holms, Dachun Liu, William McClellan, Keith McDaniel, Jasmina Marjanovic, George Sheppard, Le Wang
  • Publication number: 20160272630
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compositions comprised of one or more compounds of formula (I) are also provided.
    Type: Application
    Filed: June 27, 2014
    Publication date: September 22, 2016
    Applicant: AbbVie Inc.
    Inventors: Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James Holms, Dachun Liu, William McClellan, Keith McDaniel, Jasmina Marjanovic, George Sheppard, Le Wang
  • Publication number: 20160185769
    Abstract: The present invention provides for compounds of formula (I). wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: May 13, 2014
    Publication date: June 30, 2016
    Applicant: Abbvie Inc.
    Inventors: Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James Holms, Dachun Liu, William McClellan, Keith McDaniel, Jasmina Marjanovic, George Sheppard, Le Wang
  • Publication number: 20160143916
    Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: January 28, 2016
    Publication date: May 26, 2016
    Inventors: Le Wang, John K. Pratt, Keith F. McDaniel, Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James H. Holms, Warren M. Kati, Dachun Liu, Robert A. Mantei, William J. McClellan, George S. Sheppard, Carol K. Wada
  • Patent number: 9315488
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: April 19, 2016
    Assignee: ABBVIE INC.
    Inventors: Hong Ding, Steven W. Elmore, Lisa Hasvold, Laura A. Hexamer, Aaron R. Kunzer, William J. McClellan, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Michael D. Wendt
  • Patent number: 9303025
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: April 5, 2016
    Assignee: AbbVie Inc.
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura Hexamer, Aaron R. Kunzer, Robert A. Mantei, Cheol-Min Park, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt
  • Patent number: 9296741
    Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 29, 2016
    Assignee: AbbVie Inc.
    Inventors: Le Wang, John K Pratt, Keith F McDaniel, Yujia Dai, Steven D Fidanze, Lisa Hasvold, James H Holms, Warren M Kati, Dachun Liu, Robert A Mantei, William J McClellan, George S Sheppard, Carol K Wada
  • Publication number: 20160009687
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: May 29, 2015
    Publication date: January 14, 2016
    Inventors: Hong Ding, Steven W. Elmore, Lisa Hasvold, Laura A. Hexamer, Aaron R. Kunzer, William J. McClellan, Gerard M. Sullivan, Andrew J. Souers, Zhi-Fu Tao, Michael D. Wendt
  • Patent number: 9125913
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: September 8, 2015
    Assignee: AbbVie Inc.
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura A. Hexamer, Aaron R. Kunzer, Robert A. Mantei, William J. McClellan, Chang H. Park, Cheol-Min Park, Andrew M. Petros, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt
  • Patent number: 9072748
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: July 7, 2015
    Assignee: AbbVie Inc.
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura A. Hexamer, Aaron R. Kunzer, Robert A. Mantei, William J. McClellan, Chang H. Park, Cheol-Min Park, Andrew M. Petros, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt
  • Patent number: 9073855
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 7, 2015
    Assignee: ABBVIE INC.
    Inventors: George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura Hexamer, Robert A. Mantei, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Todd M. Hansen